Selvita S.A.

WSE:SLV Stock Report

Market Cap: zł589.2m

Selvita Valuation

Is SLV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SLV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: SLV (PLN31.6) is trading below our estimate of future cash flow value (PLN79.41)

Significantly Below Future Cash Flow Value: SLV is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLV?

Key metric: As SLV is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SLV. This is calculated by dividing SLV's market cap by their current revenue.
What is SLV's PS Ratio?
PS Ratio1.6x
Saleszł371.13m
Market Capzł589.21m

Price to Sales Ratio vs Peers

How does SLV's PS Ratio compare to its peers?

The above table shows the PS ratio for SLV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9x
RVU Ryvu Therapeutics
6.1x5.57%zł541.0m
HEN HyEnergy
23.6xn/azł77.9m
BIO BIOTON
1.3xn/azł360.6m
CLN Celon Pharma
5.1x7.84%zł1.2b
SLV Selvita
1.6x10.84%zł589.2m

Price-To-Sales vs Peers: SLV is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (9x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does SLV's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
SLV 1.6xIndustry Avg. 3.4xNo. of Companies6PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SLV is good value based on its Price-To-Sales Ratio (1.6x) compared to the European Life Sciences industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is SLV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: SLV is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SLV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł31.60
zł50.15
+58.70%
16.89%zł65.30zł40.00n/a6
May ’27zł35.00
zł50.15
+43.29%
16.89%zł65.30zł40.00n/a6
Apr ’27zł30.60
zł52.32
+70.97%
14.80%zł65.30zł40.00n/a6
Mar ’27zł43.10
zł53.25
+23.55%
13.87%zł65.30zł40.00n/a6
Feb ’27zł42.90
zł53.25
+24.13%
13.87%zł65.30zł40.00n/a6
Jan ’27zł43.20
zł52.15
+20.72%
10.48%zł58.00zł40.70n/a6
Dec ’26zł47.70
zł52.15
+9.33%
10.48%zł58.00zł40.70n/a6
Nov ’26zł36.90
zł47.48
+28.68%
16.43%zł58.00zł38.00n/a6
Oct ’26zł38.20
zł45.73
+19.72%
15.71%zł58.00zł38.00n/a6
Sep ’26zł31.30
zł49.55
+58.31%
14.67%zł58.00zł38.00n/a6
Aug ’26zł33.10
zł49.55
+49.70%
14.67%zł58.00zł38.00n/a6
Jul ’26zł29.50
zł50.66
+71.73%
14.77%zł58.00zł38.00n/a5
Jun ’26zł30.20
zł55.75
+84.60%
8.18%zł60.20zł47.00n/a6
May ’26zł33.10
zł55.75
+68.43%
8.18%zł60.20zł47.00zł35.006
Apr ’26zł37.90
zł55.75
+47.10%
8.18%zł60.20zł47.00zł30.606
Mar ’26zł46.30
zł55.75
+20.41%
8.18%zł60.20zł47.00zł43.106
Feb ’26zł44.60
zł60.08
+34.72%
15.63%zł78.70zł47.00zł42.906
Jan ’26zł49.50
zł62.15
+25.56%
16.04%zł78.70zł47.00zł43.206
Dec ’25zł51.00
zł66.40
+30.20%
11.75%zł78.70zł58.00zł47.706
Nov ’25zł53.70
zł69.23
+28.93%
11.10%zł78.70zł58.00zł36.906
Oct ’25zł57.50
zł69.65
+21.13%
10.39%zł78.70zł58.00zł38.206
Sep ’25zł67.00
zł70.98
+5.95%
7.75%zł78.70zł62.70zł31.306
Aug ’25zł68.90
zł70.98
+3.02%
7.75%zł78.70zł62.70zł33.106
Jul ’25zł67.70
zł70.98
+4.85%
7.75%zł78.70zł62.70zł29.506
Jun ’25zł66.00
zł70.98
+7.55%
7.75%zł78.70zł62.70zł30.206
May ’25zł69.60
zł68.98
-0.89%
8.48%zł78.70zł62.70zł33.105
zł50.15
Fair Value
37.0% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/08 19:52
End of Day Share Price 2026/05/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Selvita S.A. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.
Henning EsskuchenErste Group Bank AG